Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases

References

• Jancova P, Anzenbacher P, Anzenbacherova E. Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154(2):103–116.
   Google Scholar
• Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2002;300(2):355–360.
   Google Scholar
• McCarver DG, Hines RN. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002;300(2):361–366.
   Google Scholar
• Pompeo F, Brooke E, Kawamura A, et al. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics. 2002;3(1):19–30.
   Google Scholar
• Kauffman FC. Sulfonation in pharmacology and toxicology. Drug Metab Rev. 2004;36(3–4):823–843.
   Google Scholar
• Prakash C, Vaz AD. Drug metabolism: significance and challenges. Hoboken, NJ, USA: John Wiley & Sons; 2009.
   Google Scholar
• Coughtrie M. Sulfation through the looking glass—recent advances in sulfotransferase research for the curious. Pharmacogenomics J. 2002;2(5):297.
   Google Scholar
• Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact. 2000;129(1–2):141–170.
   Google Scholar
• Mueller JW, Gilligan LC, Idkowiak J, et al. The regulation of steroid action by sulfation and desulfation. Endocr Rev. 2015;36(5):526–563.
   Google Scholar
• Hemmerich S, Verdugo D, Rath VL. Strategies for drug discovery by targeting sulfation pathways. Drug Discov Today. 2004;9(22):967–975.
   Google Scholar
• Chapman E, Best MD, Hanson SR, et al. Sulfotransferases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem. 2004;43(27):3526–3548.
   Google Scholar
• Superti-Furga A. A defect in the metabolic activation of sulfate in a patient with achondrogenesis type IB. Am J Hum Genet. 1994;55(6):1137.
   Google Scholar
• Goettsch S, Badea RA, Mueller JW, et al. Human TPST1 transmembrane domain triggers enzyme dimerisation and localisation to the Golgi compartment. J Mol Biol. 2006;361(3):436–449.
   Google Scholar
• Riches Z, Stanley EL, Bloomer JC, et al. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT “pie”. Drug Metab Dispos. 2009;37(11):2255–2261.
   Google Scholar
• Miller JA. Sulfonation in chemical carcinogenesis—history and present status. Chem Biol Interact. 1994;92(1–3):329–341.
   Google Scholar
• Gamage N, Barnett A, Hempel N, et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci. 2005;90(1):5–22.
   Google Scholar
• Suzuki T, Nakata T, Miki Y, et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 2003;63(11):2762–2770.
   Google Scholar
• Song W, Moore R, McLachlan J, et al. Molecular characterization of a testis-specific estrogen sulfotransferase and aberrant liver expression in obese and diabetogenic C57BL/KsJ-db/db mice. Endocrinology. 1995;136(6):2477–2484.
   Google Scholar
• Hobkirk R, Cardy CA, Saidi F, et al. Development and characteristics of an oestrogen sulphotransferase in placenta and uterus of the pregnant mouse. Comparison between mouse and rat. Biochem J. 1983;216(2):451–457.
   Google Scholar
• Alnouti Y, Klaassen CD. Tissue distribution and ontogeny of sulfotransferase enzymes in mice. Toxicol Sci. 2006;93(2):242–255.
   Google Scholar
• Guo Y, Hu B, Huang H, et al. Estrogen sulfotransferase is an oxidative stress-responsive gene that gender-specifically affects liver ischemia/reperfusion injury. J Biol Chem. 2015;290(23):14754–14764.
   Google Scholar
• Cole GB, Keum G, Liu J, et al. Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc Nat Acad Sci. 2010;107(14):6222–6227.
   Google Scholar
• Ihunnah CA, Wada T, Philips BJ, et al. Estrogen sulfotransferase/SULT1E1 promotes human adipogenesis. Mol Cell Biol. 2014;34(9):1682–1694.
   Google Scholar
• Chai X, Guo Y, Jiang M, et al. Oestrogen sulfotransferase ablation sensitizes mice to sepsis. Nat commun. 2015;6:7979.
   Google Scholar
• Macedo LF, Sabnis G, Brodie A. Aromatase inhibitors and breast cancer. Ann N Y Acad Sci. 2009;1155(1):162–173.
   Google Scholar
• Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev. 1994;15(3):342–355.
   Google Scholar
• Purohit A, Woo LL, Potter BV. Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol. 2011;340(2):154–160.
   Google Scholar
• Mungenast F, Thalhammer T. Estrogen biosynthesis and action in ovarian cancer. Front Endocrinol (Lausanne). 2014;5:192.
   Google Scholar
• Zhang H, Varmalova O, Vargas FM, et al. Sulfuryl transfer: the catalytic mechanism of human estrogen sulfotransferase. J Biol Chem. 1998;273(18):10888–10892.
   Google Scholar
• Hernández JS, Watson R, Wood TC, et al. Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. Drug Metab Dispos. 1992;20(3):413–422.
   Google Scholar
• Petrotchenko EV, Doerflein ME, Kakuta Y, et al. Substrate gating confers steroid specificity to estrogen sulfotransferase. J Biol Chem. 1999;274(42):30019–30022.
   Google Scholar
• James MO, Li W, Summerlot DP, et al. Triclosan is a potent inhibitor of estradiol and estrone sulfonation in sheep placenta. Environ Int. 2010;36(8):942–949.
   Google Scholar
• Dao TL, Hayes C, Libby PR. Steroid sulfatase activities in human breast tumors. Pro Soc Exp Biol Med. 1974;146(2):381–384.
   Google Scholar
• Aksoy IA, Wood TC, Weinshilboum R. Human liver estrogen sulfotransferase: identification by cDNA cloning and expression. Biochem Biophys Res Commun. 1994;200(3):1621–1629.
   Google Scholar
• Schrag ML, Cui D, Rushmore TH, et al. Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Dispos. 2004;32(11):1299–1303.
   Google Scholar
• Pedersen LC, Petrotchenko E, Shevtsov S, et al. Crystal structure of the human estrogen sulfotransferase-paps complex evidence for catalytic role of Ser137 in the sulfuryl transfer reaction. J Biol Chem. 2002;277(20):17928–17932.
   Google Scholar
• Rakers C, Schumacher F, Meinl W, et al. In silico prediction of human sulfotransferase 1E1 activity guided by pharmacophores from molecular dynamics simulations. J Biol Chem. 2016;291(1):58–71.
   Google Scholar
• Landsiedel R, Engst W, Seidel A, et al. Physico-chemical properties and mutagenicity of benzylic compounds. Exp Toxicol Pathol. 1996;48:215–221.
   Google Scholar
• Reed M, Purohit A, Woo LL, et al. Steroid sulfatase: molecular biology, regulation, and inhibition. Endocr Rev. 2005;26(2):171–202.
   Google Scholar
• Jiang M, Klein M, Zanger UM, et al. Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. J Hepatol. 2016;64(1):44–52.
   Google Scholar
• Bi Y, Jiang M, Guo W, et al. Sex-dimorphic and sex hormone–dependent role of steroid sulfatase in adipose inflammation and energy homeostasis. Endocrinology. 2018;159(9):3365–3377.
   Google Scholar
• Jiang M, He J, Kucera H, et al. Hepatic over-expression of steroid sulfatase ameliorates mouse models of obesity and type 2 diabetes through sex-specific mechanisms. J Biol Chem. 2014.
   Google Scholar
• Bever AT, Hisaw FL, Velardo JT. Inhibitory action of desoxycorticosterone acetate, cortisone acetate, and testosterone on uterine growth induced by estradiol-17beta. Endocrinology. 1956 Aug;59(2):165–169.
   Google Scholar
• Campbell PS. The mechanism of the inhibition of uterotrophic responses by acute dexamethasone pretreatment. Endocrinology. 1978 Sep;103(3):716–723.
   Google Scholar
• Rhen T, Grissom S, Afshari C, et al. Dexamethasone blocks the rapid biological effects of 17beta-estradiol in the rat uterus without antagonizing its global genomic actions. Faseb J. 2003 Oct;17(13):1849–1870.
   Google Scholar
• Gong H, Jarzynka MJ, Cole TJ, et al. Glucocorticoids antagonize estrogens by glucocorticoid receptor–mediated activation of estrogen sulfotransferase. Cancer Res. 2008;68(18):7386–7393.
   Google Scholar
• Sahlin L. Dexamethasone attenuates the estradiol-induced increase of IGF-I mRNA in the rat uterus. J Steroid Biochem Mol Biol. 1995 Oct;55(1):9–15.
   Google Scholar
• Zhou F, Bouillard B, Pharaboz-Joly MO, et al. Non-classical antiestrogenic actions of dexamethasone in variant MCF-7 human breast cancer cells in culture. Mol Cell Endocrinol. 1989 Oct;66(2):189–197.
   Google Scholar
• Gong H, Guo P, Zhai Y, et al. Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol Endocrinol. 2007;21(8):1781–1790.
   Google Scholar
• Alnouti Y, Klaassen CD. Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice. J Pharmacol Exp Ther. 2008;324(2):612–621.
   Google Scholar
• Kang HS, Angers M, Beak JY, et al. Gene expression profiling reveals a regulatory role for RORα and RORγ in phase I and phase II metabolism. Physiol Genomics. 2007;31(2):281–294.
   Google Scholar
• Kodama S, Hosseinpour F, Goldstein JA, et al. Liganded pregnane X receptor represses the human sulfotransferase SULT1E1 promoter through disrupting its chromatin structure. Nucleic Acids Res. 2011;39(19):8392–8403.
   Google Scholar
• Wang S, Yuan X, Lu D, et al. farnesoid X receptor regulates Sult1e1 expression through inhibition of Pgc1α binding to Hnf4α. Biochem Pharmacol. 2017;145:202–209.
   Google Scholar
• Wang B, Sanchez RI, Franklin RB, et al. The involvement of cyp3a4 and cyp2c9 in the metabolism of 17α-ethinylestradiol. Drug Metabolism and Disposition. 2004;32(11):1209-1212. doi:10.1124/dmd.104.000182
   Google Scholar
• Back D, Breckenridge A, MacIver M, et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre‐systemic metabolism of ethinyloestradiol in humans. Br J Clin Pharmacol. 1982;13(3):325–330.
   Google Scholar
• Bolt H, Bolt M, Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinologica. 1977;85(1):189–197.
   Google Scholar
• Back D, Breckenridge A, MacIver M, et al. Interaction of ethinyloestradiol with ascorbic acid in man. Br Med J (Clinical Research Ed). 1981;282(6275):1516.
   Google Scholar
• Rogers SM, Back D, Stevenson P, et al. Paracetamol interaction with oral contraceptive steroids: increased plasma concentrations of ethinyloestradiol. Br J Clin Pharmacol. 1987;23(6):721–725.
   Google Scholar
• Sinofsky FE, Pasquale SA. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives. Am J Clin Exp Obstet Gynecol. 1998;178(2):300–304.
   Google Scholar
• De Montellano PO, Kunze KL. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J Biol Chem. 1980;255(12):5578–5585.
   Google Scholar
• De Montellano PO, Kunze KL, Yost GS, et al. Self-catalyzed destruction of cytochrome P-450: covalent binding of ethynyl sterols to prosthetic heme. Proc Nat Acad Sci. 1979;76(2):746–749.
   Google Scholar
• Kent UM, Mills DE, Rajnarayanan RV, et al. Effect of 17-α-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther. 2002;300(2):549–558.
   Google Scholar
• Lin H-L, Kent UM, Hollenberg PF. Mechanism-based inactivation of cytochrome P450 3A4 by 17α-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther. 2002;301(1):160–167.
   Google Scholar
• Madden S, Back D, Martin C, et al. Metabolism of the contraceptive steroid desogestrel by the intestinal mucosa. Br J Clin Pharmacol. 1989;27(3):295–299.
   Google Scholar
• Falany JL, Pilloff DE, Leyh TS, et al. Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases. Drug Metab Dispos. 2006;34(3):361–368.
   Google Scholar
• Falany JL, Macrina N, Falany CN. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol. 2004;88(4–5):383–391.
   Google Scholar
• Bhavnani BR, Stanczyk FZ. Pharmacology of conjugated equine estrogens: efficacy, safety and mechanism of action. J Steroid Biochem Mol Biol. 2014;142:16–29.
   Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349(6):523–534.
   Google Scholar
• Gambacciani M, Levancini M. Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz menopauzalny. 2014;13(4):213.
   Google Scholar
• Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the women’s health initiative memory study: a randomized controlled trial. JAMA. 2003;289(20):2663–2672.
   Google Scholar
• Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women’s health initiative memory study. JAMA. 2004;291(24):2947–2958.
   Google Scholar
• Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women’s health initiative memory study: a randomized controlled trial. JAMA. 2003;289(20):2651–2662.
   Google Scholar
• Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultra–low-dose transdermal estradiol on cognition and health-related quality of life. Arch Neurol. 2006;63(7):945–950.
   Google Scholar
• Wroolie TE, Kenna HA, Williams KE, et al. Cognitive effects of hormone therapy continuation or discontinuation in a sample of women at risk for Alzheimer disease. Am J Geriatric Psychiatry. 2015;23(11):1117–1126.
   Google Scholar
• Park-Chung M, Malayev A, Purdy RH, et al. Sulfated and unsulfated steroids modulate γ-aminobutyric acidA receptor function through distinct sites. Brain Res. 1999;830(1):72–87.
   Google Scholar
• Skakkebék NE, Meyts ERD, Jørgensen N, et al. Germ cell cancer and disorders of spermatogenesis: an environmental connection? APMIS. 1998;106(1–6):3–12.
   Google Scholar
• Safe SH. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. Crit Rev Toxicol. 1994;24(2):87–149.
   Google Scholar
• Kester MH, Bulduk S, Tibboel D, et al. Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology. 2000;141(5):1897–1900.
   Google Scholar
• Basly J-P, Lavier M-C-C. Dietary phytoestrogens: potential selective estrogen enzyme modulators? Planta Med. 2005;71(04):287–294.
   Google Scholar
• Harris R, Wood D, Bottomley L, et al. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab. 2004;89(4):1779–1787.
   Google Scholar
• Miksits M, Maier-Salamon A, Aust S, et al. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica. 2005;35(12):1101–1119.
   Google Scholar
• Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metabolism and Disposition. 2004;32(12):1377-1382. doi:10.1124/dmd.104.000885
   Google Scholar
• Otake Y, Nolan AL, Walle UK, et al. Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol. 2000;73(5):265–270.
   Google Scholar
• Adolfsson-Erici M, Pettersson M, Parkkonen J, et al. Triclosan, a commonly used bactericide found in human milk and in the aquatic environment in Sweden. Chemosphere. 2002;46(9–10):1485–1489.
   Google Scholar
• Calafat AM, Ye X, Wong L-Y, et al. Urinary concentrations of triclosan in the US population: 2003–2004. Environ Health Perspect. 2007;116(3):303–307.
   Google Scholar
• Stoker TE, Gibson EK, Zorrilla LM. Triclosan exposure modulates estrogen-dependent responses in the female wistar rat. Toxicol Sci. 2010;117(1):45–53.
   Google Scholar
• Song W-C, Qian Y, Li AP. Estrogen sulfotransferase expression in the human liver: marked interindividual variation and lack of gender specificity. J Pharmacol Exp Ther. 1998;284(3):1197–1202.
   Google Scholar
• Adjei AA, Thomae BA, Prondzinski JL, et al. Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. Br J Pharmacol. 2003;139(8):1373–1382.
   Google Scholar
• Rebbeck TR, Troxel AB, Wang Y, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst. 2006;98(18):1311–1320.
   Google Scholar
• Tong MH, Jiang H, Liu P, et al. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase—deficient mice. Nat Med. 2005;11(2):153.
   Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605–613.
   Google Scholar
• Cancer CGoHFiB. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997;350(9084):1047–1059.
   Google Scholar
• Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328(15):1069–1075.
   Google Scholar
• Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348(9033):977–980.
   Google Scholar
• Šmuc T, Rižner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol. 2009;301(1–2):74–82.
   Google Scholar
• Ren X, Wu X, Hillier SG, et al. Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy. J Steroid Biochem Mol Biol. 2015;150:54–63.
   Google Scholar
• Pasqualini JR. Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad Sci. 2009;1155(1):88–98.
   Google Scholar
• Sasano H, Miki Y, Nagasaki S, et al. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int. 2009;59(11):777–789.
   Google Scholar
• Wang L-J, Li J, Hao F-R, et al. Dexamethasone suppresses the growth of human non-small cell lung cancer via inducing estrogen sulfotransferase and inactivating estrogen. Acta Pharmacol Sin. 2016;37(6):845.
   Google Scholar
• Li L, He D, Wilborn TW, et al. Increased SULT1E1 activity in HepG2 hepatocytes decreases growth hormone stimulation of STAT5b phosphorylation. Steroids. 2009;74(1):20–29.
   Google Scholar
• Piccinato CA, Neme RM, Torres N, et al. Effects of steroid hormone on estrogen sulfotransferase and on steroid sulfatase expression in endometriosis tissue and stromal cells. J Steroid Biochem Mol Biol. 2016;158:117–126.
   Google Scholar
• Wada T, Ihunnah CA, Gao J, et al. Estrogen sulfotransferase inhibits adipocyte differentiation. Mol Endocrinol. 2011;25(9):1612–1623.
   Google Scholar
• Leiter EH, Chapman HD. Obesity-induced diabetes (diabesity) in C57BL/KsJ mice produces aberrant trans-regulation of sex steroid sulfotransferase genes. J Clin Invest. 1994;93(5):2007–2013.
   Google Scholar
• Gao J, He J, Shi X, et al. Sex-specific effect of estrogen sulfotransferase on mouse models of type 2 diabetes. Diabetes. 2012;61(6):1543–1551.
   Google Scholar
• Garbacz WG, Jiang M, Xu M, et al. Sex-and tissue-specific role of estrogen sulfotransferase in energy homeostasis and insulin sensitivity. Endocrinology. 2017;158(11):4093–4104.
   Google Scholar
• Durie PR, Kent G, Phillips MJ, et al. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol. 2004;164(4):1481–1493.
   Google Scholar
• Kerem B-S, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073–1080.
   Google Scholar
• Rosenberg LA, Schluchter MD, Parlow AF, et al. Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res. 2006;59(2):191.
   Google Scholar
• Ozen M, Cokugras H, Ozen N, et al. Relation between serum Insulin‐like growth factor‐I and insulin‐like growth factor‐binding protein‐3 levels, clinical status and growth parameters in prepubertal cystic fibrosis patients. Pediatr Int. 2004;46(4):429–435.
   Google Scholar
• Boguszewski MC, Kamoi TO, Radominski RB, et al. Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis. Hormone Res Paediatrics. 2007;67(5):250–256.
   Google Scholar
• Li L, Falany CN. Elevated hepatic SULT1E1 activity in mouse models of cystic fibrosis alters the regulation of estrogen responsive proteins. J Cyst Fibros. 2007;6(1):23–30.
   Google Scholar
• Falany CN, He D, Li L, et al. Regulation of hepatic sulfotransferase (SULT) 1E1 expression and effects on estrogenic activity in cystic fibrosis (CF). J Steroid Biochem Mol Biol. 2009;114(1–2):113–119.
   Google Scholar